RBM3 and prostate cancer: This viewpoint is challenged by the results presented here, but, evidently, drug induced effects by RBM3 modulation seem to differ between different cell line models, as down-regulation of RBM3 has been associated with enhanced response to adriamycin and cisplatin in androgen dependent but not androgen-independent prostate cancer cells [35].